Denali Capital Acquisition Corp. (DNQAF)
| Market Cap | 31.53M |
| Revenue (ttm) | n/a |
| Net Income | -1.46M |
| EPS | -0.45 |
| Shares Out | 2.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Average Volume | 1,001 |
| Open | 12.05 |
| Previous Close | 11.54 |
| Day's Range | 12.05 - 12.05 |
| 52-Week Range | 10.52 - 13.20 |
| Beta | 0.20 |
| RSI | 51.44 |
| Earnings Date | Nov 14, 2025 |
About DNQAF
Denali Capital Acquisition Corp. does not have significant operations. It intends to affect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses in technology, consumer, and hospitality sectors. The company was incorporated in 2022 and is based in New York, New York. [Read more]
News
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company's trust account (the “Trust...
Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that on April 11, 2025, the Company's shareholders voted in favor ...
Denali Capital Acquisition Corp. Announces Adjournment of Extraordinary General Meeting of Shareholders to April 11, 2025 at 10:00 AM ET.
NEW YORK, NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that the Company's Extraordinary General Meeting of Shareholders ...
Semnur Pharmaceuticals to go public via SPAC merger with Denali Capital in $2.5 bln deal
Semnur Pharmaceuticals, a wholly owned subsidiary of Scilex Holding Company , will go public via a merger with special purpose acquisition company Denali Capital Acquisition Corp in a $2.5 billion dea...
Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut
Semnur Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company SCLX, and Denali Capital Acquisition Corp. DECA, a special purpose acquisition company, signed a letter of intent for a...
Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital
Drug developer Semnur Pharmaceuticals said on Tuesday it has signed a letter of intent to go public through a merger with special purpose acquisition company Denali Capital Acquisition Corp in a pre-t...
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination
PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-genera...
Correction: Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed ...
Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed ...
Denali Capital Acquisition Corp. Announces Postponement of Extraordinary General Meeting From Thursday, January 4, 2024 to Tuesday, January 9, 2024
NEW YORK , Dec. 29, 2023 /PRNewswire/ -- Denali Capital Acquisition Corp. (Nasdaq: DECA) (the "Company") announced today that its previously announced extraordinary general meeting (the "Shareholder M...
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete an Initial Business Combination
NEW YORK , July 13, 2023 /PRNewswire/ -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that an aggregate of $825,000 has been deposited into the Company's...
Denali Capital Acquisition Corp. Announces Intention to Extend Deadline to Complete an Initial Business Combination
NEW YORK , July 7, 2023 /PRNewswire/ -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that it intends to deposit into the Company's trust account an aggre...
Denali Capital Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing May 31, 2022.
NEW YORK , May 26, 2022 /PRNewswire/ -- Denali Capital Acquisition Corp. (NASDAQ: DECAU) ("Denali" or the "Company") announced today that, commencing May 31, 2022, holders of units (the "Units") sold ...